Valeritas Announces V-Go® Distribution Agreement in Australia and New Zealand

BRIDGEWATER, N.J., April 17, 2018 (GLOBE NEWSWIRE) — Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers patients with type 2 diabetes V-Go® Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch and can eliminate the need for taking multiple daily shots, announced today that it signed an exclusive distribution agreement with AMSL Diabetes and NZMS Diabetes for the commercialization of its V-Go® Wearable Insulin Delivery device in Australia and New Zealand. Under the terms of the agreement, AMSL Diabetes and NZMS Diabetes will have the rights to promote, market and sell the V-Go to diabetes clinics and patients in Australia and New Zealand.